Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 2.6/5
Laurus Labs (LAURUS IN)
Watchlist
Contact IR
62
Analysis
Health Care
•
India
Laurus Labs Limited researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India and internationally. It offers APIs for anti-retroviral and hepatitis C; and APIs in oncology and other therapeutic areas. .
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Concord Biotech Ltd
•
10 Jun 2024 16:37
Concord Biotech Ltd (CONCORDB IN): Accelerated Growth Ahead; Recent Pullback Comforted Valuation
Concord Biotech aims for 25% revenue CAGR in 3–5 years with focus on market penetration, acquiring new customers, and introducing new products....
Tina Banerjee
Follow
431 Views
Share
bullish
•
Concord Biotech Ltd
•
28 May 2024 02:28
Concord Biotech's US$650m Lock-Up Expiry - Some Could Be Tempted to Book Multi-Bagger Gains
Ontario is looking to raise US$56m from selling a 3.4% stake in Concord Biotech. The deal has a floor price of INR1,320/share, at a 8.5% discount...
Clarence Chu
Follow
573 Views
Share
bullish
•
Gland Pharma Ltd
•
08 Apr 2024 13:43
Gland Pharma Ltd (GLAND IN): Business Recovery Seems To Be Overlooked by Mr. Market
Gland Pharma reports steady growth in base business and is confident to end FY24 on high note. While the US will remain main growth driver, the...
Tina Banerjee
Follow
504 Views
Share
bullish
•
Union Bank Of India
•
19 Dec 2023 22:11
AMFI Stock Reclassification Preview (Dec 2023): MidCap to LargeCap Migrations Outperforming
We see 41 stocks migrating between different market cap segments in Jan. A lot of stocks will have passive flows from NIFTY, NIFTYJR and global...
Brian Freitas
Follow
530 Views
Share
bullish
•
Concord Biotech Ltd
•
01 Dec 2023 11:25
Concord Biotech Ltd (658823Z IN): Q2 EBITDA and PAT Triples on Operational Efficiencies
In Q2FY24, Concord’s EBITDA and PAT grew to INR1,160M and INR810M from INR370M and INR220M, respectively in Q2FY23. With new capacities coming on...
Tina Banerjee
Follow
572 Views
Share
First
Previous
3
4
5
6
7
8
9
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.3
x